180 related articles for article (PubMed ID: 14617803)
21. Differential posttranscriptional regulation of androgen receptor gene expression by androgen in prostate and breast cancer cells.
Yeap BB; Krueger RG; Leedman PJ
Endocrinology; 1999 Jul; 140(7):3282-91. PubMed ID: 10385425
[TBL] [Abstract][Full Text] [Related]
22. Gene expression changes following androgen receptor elimination in LNCaP prostate cancer cells.
Eder IE; Haag P; Basik M; Mousses S; Bektic J; Bartsch G; Klocker H
Mol Carcinog; 2003 Aug; 37(4):181-91. PubMed ID: 12891627
[TBL] [Abstract][Full Text] [Related]
23. HOXC8 inhibits androgen receptor signaling in human prostate cancer cells by inhibiting SRC-3 recruitment to direct androgen target genes.
Axlund SD; Lambert JR; Nordeen SK
Mol Cancer Res; 2010 Dec; 8(12):1643-55. PubMed ID: 21047772
[TBL] [Abstract][Full Text] [Related]
24. Sodium selenite inhibits interleukin-6-mediated androgen receptor activation in prostate cancer cells via upregulation of c-Jun.
Gazi MH; Gong A; Donkena KV; Young CY
Clin Chim Acta; 2007 May; 380(1-2):145-50. PubMed ID: 17346688
[TBL] [Abstract][Full Text] [Related]
25. Prostate specific antigen expression is down-regulated by selenium through disruption of androgen receptor signaling.
Dong Y; Lee SO; Zhang H; Marshall J; Gao AC; Ip C
Cancer Res; 2004 Jan; 64(1):19-22. PubMed ID: 14729601
[TBL] [Abstract][Full Text] [Related]
26. Selenomethionine induced transcriptional programs in human prostate cancer cells.
Zhao H; Brooks JD
J Urol; 2007 Feb; 177(2):743-50. PubMed ID: 17222674
[TBL] [Abstract][Full Text] [Related]
27. Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells.
Zhao XY; Ly LH; Peehl DM; Feldman D
Endocrinology; 1999 Mar; 140(3):1205-12. PubMed ID: 10067845
[TBL] [Abstract][Full Text] [Related]
28. Upregulation of prostate-derived Ets factor by luteolin causes inhibition of cell proliferation and cell invasion in prostate carcinoma cells.
Tsui KH; Chung LC; Feng TH; Chang PL; Juang HH
Int J Cancer; 2012 Jun; 130(12):2812-23. PubMed ID: 21780100
[TBL] [Abstract][Full Text] [Related]
29. Resveratrol-induced gene expression profiles in human prostate cancer cells.
Jones SB; DePrimo SE; Whitfield ML; Brooks JD
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):596-604. PubMed ID: 15767336
[TBL] [Abstract][Full Text] [Related]
30. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation.
Kokontis J; Takakura K; Hay N; Liao S
Cancer Res; 1994 Mar; 54(6):1566-73. PubMed ID: 7511045
[TBL] [Abstract][Full Text] [Related]
31. Valproic acid induces neuroendocrine differentiation and UGT2B7 up-regulation in human prostate carcinoma cell line.
Valentini A; Biancolella M; Amati F; Gravina P; Miano R; Chillemi G; Farcomeni A; Bueno S; Vespasiani G; Desideri A; Federici G; Novelli G; Bernardini S
Drug Metab Dispos; 2007 Jun; 35(6):968-72. PubMed ID: 17371798
[TBL] [Abstract][Full Text] [Related]
32. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
Koochekpour S; Lee TJ; Wang R; Culig Z; Delorme N; Caffey S; Marrero L; Aguirre J
Prostate; 2007 Feb; 67(2):178-89. PubMed ID: 17044040
[TBL] [Abstract][Full Text] [Related]
33. Estrogen receptor activation and estrogen-regulated gene expression are unaffected by methylseleninic acid in LNCaP prostate cancer cells.
Parker TL; Eggett DL; Christensen MJ
J Nutr Biochem; 2007 Nov; 18(11):746-52. PubMed ID: 17434722
[TBL] [Abstract][Full Text] [Related]
34. Identification of novel androgen receptor target genes in prostate cancer.
Jariwala U; Prescott J; Jia L; Barski A; Pregizer S; Cogan JP; Arasheben A; Tilley WD; Scher HI; Gerald WL; Buchanan G; Coetzee GA; Frenkel B
Mol Cancer; 2007 Jun; 6():39. PubMed ID: 17553165
[TBL] [Abstract][Full Text] [Related]
35. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells.
Weiss-Messer E; Merom O; Adi A; Karry R; Bidosee M; Ber R; Kaploun A; Stein A; Barkey RJ
Mol Cell Endocrinol; 2004 May; 220(1-2):109-23. PubMed ID: 15196705
[TBL] [Abstract][Full Text] [Related]
36. Effects of herbal preparation Equiguard on hormone-responsive and hormone-refractory prostate carcinoma cells: mechanistic studies.
Hsieh TC; Lu X; Guo J; Xiong W; Kunicki J; Darzynkiewicz Z; Wu JM
Int J Oncol; 2002 Apr; 20(4):681-9. PubMed ID: 11894110
[TBL] [Abstract][Full Text] [Related]
37. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
[TBL] [Abstract][Full Text] [Related]
38. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens.
Waltering KK; Helenius MA; Sahu B; Manni V; Linja MJ; Jänne OA; Visakorpi T
Cancer Res; 2009 Oct; 69(20):8141-9. PubMed ID: 19808968
[TBL] [Abstract][Full Text] [Related]
39. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.
Arnold JT; Le H; McFann KK; Blackman MR
Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E573-84. PubMed ID: 15536203
[TBL] [Abstract][Full Text] [Related]
40. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells.
Sadar MD; Gleave ME
Cancer Res; 2000 Oct; 60(20):5825-31. PubMed ID: 11059779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
